LU90297I2 - Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate - Google Patents

Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate

Info

Publication number
LU90297I2
LU90297I2 LU90297C LU90297C LU90297I2 LU 90297 I2 LU90297 I2 LU 90297I2 LU 90297 C LU90297 C LU 90297C LU 90297 C LU90297 C LU 90297C LU 90297 I2 LU90297 I2 LU 90297I2
Authority
LU
Luxembourg
Prior art keywords
rivastigmine
derivatives
pharmaceutically acceptable
acceptable salts
hydrogen tartrate
Prior art date
Application number
LU90297C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90297(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU90297I2 publication Critical patent/LU90297I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LU90297C 1987-03-04 1998-10-07 Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate LU90297I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04

Publications (1)

Publication Number Publication Date
LU90297I2 true LU90297I2 (fr) 1998-12-07

Family

ID=6322236

Family Applications (2)

Application Number Title Priority Date Filing Date
LU87150A LU87150A1 (fr) 1987-03-04 1988-03-02 Nouveau carbamate de phenyle,sa preparation et son utilisation comme medicament
LU90297C LU90297I2 (fr) 1987-03-04 1998-10-07 Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU87150A LU87150A1 (fr) 1987-03-04 1988-03-02 Nouveau carbamate de phenyle,sa preparation et son utilisation comme medicament

Country Status (29)

Country Link
US (1) US5602176A (fr)
JP (3) JP2625478B2 (fr)
KR (1) KR0133686B1 (fr)
AT (1) AT394190B (fr)
AU (1) AU618949B2 (fr)
BE (1) BE1001467A3 (fr)
CA (1) CA1307003C (fr)
CH (1) CH675720A5 (fr)
CS (1) CS411091A3 (fr)
CY (1) CY1735A (fr)
DK (1) DK175762B1 (fr)
ES (1) ES2010527A6 (fr)
FI (1) FI89165C (fr)
FR (1) FR2611707B1 (fr)
GB (1) GB2203040C (fr)
GR (1) GR1000023B (fr)
HK (1) HK110093A (fr)
HU (1) HU201906B (fr)
IE (1) IE61714B1 (fr)
IL (1) IL85609A (fr)
IT (1) IT1219853B (fr)
LU (2) LU87150A1 (fr)
MY (1) MY103225A (fr)
NL (1) NL195004C (fr)
NZ (1) NZ223714A (fr)
PT (1) PT86875B (fr)
SA (1) SA93140384B1 (fr)
SE (1) SE8800731A0 (fr)
ZA (1) ZA881584B (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
FI964113L (fi) * 1994-04-15 1996-10-14 Iyo Masaomi Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö
AU5620998A (en) * 1996-12-18 1998-07-15 Technion Research & Development Foundation Ltd. Phenylethylamine derivatives
CA2275425C (fr) 1996-12-18 2009-08-04 Michael Chorev Derives d'aminoindan
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
IL141762A0 (en) 1998-10-01 2002-03-10 Novartis Ag New oral formulations
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
CA2354035A1 (fr) * 1998-12-11 2000-06-15 Bonnie Davis Utilisation d'inhibiteurs d'acetylcholine esterase pour la modulation de l'axe hypothalamo-hypophyso-gonadique
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ293014B6 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
EP1603548A4 (fr) * 2003-02-05 2007-10-10 Myriad Genetics Inc Composition et methode de traitement de troubles neurodegeneratifs
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2005065069A2 (fr) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
US7897639B2 (en) * 2003-10-21 2011-03-01 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
GB2409453A (en) 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
WO2006001877A2 (fr) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
WO2005108683A1 (fr) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Placages pour parois, murs de soutenement et analogues
EP1779867A4 (fr) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd Promoteur de la régénérescence nerveuse
WO2006020850A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
CA2618985A1 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
WO2006020852A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
RU2393148C2 (ru) * 2004-11-08 2010-06-27 Эмкюр Фармасьютикалз Лимитед Способ получения (s)-3-[(1-диметиламино)этил]-фенил-n-этил-n-метил-карбамата
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
CA2615063A1 (fr) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. Formes posologiques et preparations a charge medicamenteuse elevee
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
ATE546202T1 (de) 2005-09-15 2012-03-15 Sony Computer Entertainment Inc Kabelloser videospielcontroller und verfahren zum betreiben des kabellosen videospielcontrollers
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
JP2009518433A (ja) * 2005-12-09 2009-05-07 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム 神経保護用の低用量ラドスチギルの使用
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
EP2046119A2 (fr) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Traitement de troubles psychiatriques
DE602006015241D1 (de) * 2006-08-17 2010-08-12 Alembic Ltd Verbessertes verfahren zur herstellung von rivastigmin
WO2008037433A1 (fr) 2006-09-29 2008-04-03 Synthon B.V. Procédé de fabrication de carbamates d'aminoalkylphényle et intermédiaires de cette fabrication
EP2420235A1 (fr) 2006-10-27 2012-02-22 Medivation Neurology, Inc. Procédés et polythérapies pour traiter la maladie d'Alzheimer
EP1942100A1 (fr) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Formes amorphes et cristallines dýhydrogénotartrate de rivastigmine
US8101782B2 (en) * 2007-02-02 2012-01-24 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
US8013181B2 (en) * 2007-04-10 2011-09-06 Dr. Reddy's Laboratories Limited Preparation of rivastigmine and its salts
WO2008124969A1 (fr) * 2007-04-16 2008-10-23 Topharman Shanghai Co., Ltd. Méthode de préparation de rivastigmine et de ses intermédiaires
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2009011901A2 (fr) * 2007-07-18 2009-01-22 Colucid Pharmaceuticals, Inc. Procédés pour favoriser la veille
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
CN101910110B (zh) * 2008-01-10 2013-05-22 上海医药工业研究院 利凡斯的明的制备方法、其中间体以及中间体的制备方法
EP2349976B1 (fr) 2008-08-25 2012-12-26 Jubilant Life Sciences Limited Procédé de production de (s)-3-[(1-diméthylamino)éthyl]phényl-n-éthyl-n-méthyl-carbamate par le biais de nouveaux intermédiaires
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) * 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
WO2011076621A2 (fr) 2009-12-22 2011-06-30 Acino Ag Système thérapeutique transdermique servant à administrer de la rivastigmine ou ses dérivés
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
EP2533645B1 (fr) 2010-02-09 2016-07-27 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
JP6088422B2 (ja) 2010-03-29 2017-03-01 ノバルティス アーゲー ウイルス様粒子に結合しているアミロイドベータ１−６ペプチドおよびアジュバントを含む組成物
WO2011151359A1 (fr) 2010-06-02 2011-12-08 Noscira, S.A. Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione
WO2011151669A1 (fr) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Procédé de production d'un isomère énantiomériquement enrichi d'un dérivé du 3-(1-aminoéthyle) phényle et son utilisation pour produire de la rivastigmine ou son sel pharmaceutiquement acceptable
DK2582799T3 (en) 2010-06-17 2018-02-12 Codexis Inc BIOCATALATORS AND PROCEDURES FOR THE SYNTHESIS OF (S) -3- (1-AMINOETHYL) -PHENOL
AU2011328993B2 (en) 2010-11-15 2017-03-02 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
SI2468274T1 (sl) 2010-12-14 2015-10-30 Acino Ag Transdermalni terapevtski sistem za dajanje aktivne snovi
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
JP6017543B2 (ja) 2011-05-20 2016-11-02 エスケー ケミカルズ カンパニー, リミテッドSk Chemicals Co., Ltd. リバスティグミン含有パッチ
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
US9333182B2 (en) 2011-08-31 2016-05-10 Sekisui Medical Co., Ltd. Adhesive patch
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (fr) 2011-11-18 2013-05-22 Labtec GmbH Composition pour administration transdermique de rivastigmine
WO2013142339A1 (fr) 2012-03-23 2013-09-26 Novartis Ag Système thérapeutique transdermique et procédé associé
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (fr) 2013-01-15 2014-07-24 Zydus Technologies Limited Système d'administration de médicament pharmaceutique transdermique stable comprenant de la rivastigmine
CA2904767C (fr) 2013-03-15 2022-06-21 Agenebio, Inc. Procedes et compositions pour ameliorer la fonction cognitive
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
CA2921308A1 (fr) 2013-08-16 2015-02-19 Universiteit Maastricht Traitement d'une deficience cognitive a l'aide d'un inhibiteur de pde4
EP4032889B1 (fr) 2013-12-20 2026-05-06 Agenebio, Inc. Dérivés de benzodiazépine, compositions et méthodes de traitement de déficience cognitive
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
EP3310785B1 (fr) 2015-06-19 2024-11-20 Agenebio, Inc. Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2019288382B2 (en) 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
EP4572852A1 (fr) 2022-08-19 2025-06-25 Agenebio, Inc. Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive
WO2025038382A1 (fr) 2023-08-11 2025-02-20 Momentive Performance Materials Inc. Compositions adhésives pharmaceutiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.

Also Published As

Publication number Publication date
DK112588A (da) 1988-09-05
FI880972L (fi) 1988-09-05
ES2010527A6 (es) 1989-11-16
SA93140384B1 (ar) 2006-04-04
US5602176A (en) 1997-02-11
KR880011088A (ko) 1988-10-26
SE8800731D0 (sv) 1988-03-02
FI880972A0 (fi) 1988-03-02
HK110093A (en) 1993-10-29
IE61714B1 (en) 1994-11-30
HUT49325A (en) 1989-09-28
HU201906B (en) 1991-01-28
LU87150A1 (fr) 1988-11-17
FI89165C (fi) 1993-08-25
KR0133686B1 (ko) 1998-04-21
GB2203040B (en) 1990-10-24
JP2625478B2 (ja) 1997-07-02
PT86875B (pt) 1992-05-29
JPS63238054A (ja) 1988-10-04
AU618949B2 (en) 1992-01-16
ATA55188A (de) 1991-08-15
NL195004C (nl) 2003-11-04
JPH09118617A (ja) 1997-05-06
GB2203040A (en) 1988-10-12
NL8800436A (nl) 1988-10-03
JPH09165362A (ja) 1997-06-24
NZ223714A (en) 1994-05-26
IL85609A (en) 1992-07-15
SE8800731L (sv) 1988-09-05
BE1001467A3 (fr) 1989-11-07
GR880100125A (en) 1989-01-31
GR1000023B (el) 1990-01-31
GB8804888D0 (en) 1988-03-30
IT1219853B (it) 1990-05-24
SE8800731A0 (sv) 1988-09-05
IT8847693A0 (it) 1988-03-04
FR2611707B1 (fr) 1990-04-20
CA1307003C (fr) 1992-09-01
IL85609A0 (en) 1988-08-31
ZA881584B (en) 1989-11-29
DK175762B1 (da) 2005-02-14
MY103225A (en) 1993-05-29
JP2859225B2 (ja) 1999-02-17
GB2203040C (en) 2014-07-30
CH675720A5 (fr) 1990-10-31
IE880583L (en) 1988-09-04
PT86875A (pt) 1988-04-01
AU1255488A (en) 1988-09-08
AT394190B (de) 1992-02-10
FI89165B (fi) 1993-05-14
FR2611707A1 (fr) 1988-09-09
CY1735A (en) 1994-06-03
NL195004B (nl) 2003-07-01
DK112588D0 (da) 1988-03-02
CS411091A3 (en) 1992-12-16

Similar Documents

Publication Publication Date Title
LU91131I2 (fr) Duloxétine et ses sels d&#39;addition acides pharmaceutiquement acceptables, et en particulier, chlorhydrate de duloxétine.
LU90866I2 (fr) Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d&#39;hydrochlorurede sibutramine
LU88842I2 (fr) Nebivolol optionnellement sous forme d&#39;un sel ou d&#39;un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU90098I2 (fr) Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique
LU91599I2 (fr) Lasofoxifene, optionnellement sous forme d&#39;un sel d&#39;addition acide, d&#39;un N-oxyde, d&#39;unester ou d&#39;un sel d&#39;ammonium quaternaire, non toxiques et pharmacologiquement acceptables, y compris le sel tartrate (FABLYN - lasofoxifene)
LU91802I2 (fr) Telmisartan, éventuellement sous forme de sels pharmacologiquement acceptables et Amlodipine, éventuellement sous forme de sels pharmacologiquement acceptables, en particulier le bésylate d&#39;Amlodipine
LU90593I2 (fr) Quetiapine facutativement sous forme d&#39;un sel pharmaceutiquement acceptabe
LU91306I2 (fr) Mitratapide, optionnellement sous forme d&#39;un sel d&#39;addition acide pharmaceutiquement acceptable (YARVITAN)
EG18266A (en) Improvements in pharmaceutically acceptable salts
FI872379A7 (fi) Menetelmä farmakologisesti vaikuttavien 1,5-diaryyli-3-(w-substituoitu-alempi-alkyyli)-pyratsolien valmistamiseksi
GR3017367T3 (en) composition in the form of a foam containing 5-aminosalicylic acid for intra-rectal administration.
LU88809I2 (fr) Lamivudine facultativement sous la forme d&#39;un sel pharmaceutiquement acceptable
FI891338L (fi) Parannus menetelmään 2&#39;,3&#39;-dideoksi-2&#39;,3&#39;-didehydronukleosidien valmistamiseksi
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
PT84041A (en) Process for the preparation of optically pure s-(-)-1-propyl-2:,6:-pipecoloxylidide hydrochloride monohydrate and of pharmaceutical compositions containing the same
IL87339A0 (en) 2-((4-piperidyl)methyl)-1,2,3-4-tetrahydroisoquinoline derivatives,their preparation and their application in therapy
BG101884A (en) Salts of the clavulanic acid
FI900145L (fi) Menetelmä farmaseuttisesti käyttökelpoisten 1,1-diokso-kefem-4-karbotiolihappojohdannaisten valmistamiseksi
CS621687A2 (en) Metod of 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonine&#39;s or 1,4-benzoxazonine&#39;s pharmacologically active,pain alleviating derivatives production
FI893121L (fi) Menetelmä farmakologisesti aktiivisten 6,21-dimetyyli-19-norprogesteronijohdannaisten valmistamiseksi
GR3024940T3 (en) Gestagenically active 19,11-bridged 4-estrenes.
NZ224812A (en) Derivatives of 2&#39;,3&#39;-dideoxycytidine and pharmaceutical compositions
FI894813A0 (fi) Menetelmä terapeuttisesti aktiivisten 2-metoksikarbonyylisubstituoitujen N,N&#39;-di(trimetoksibentsoyyli)piperatsiinijohdannaisten valmistamiseksi
FR2607676B1 (fr) Procede d&#39;obtention de compositions alimentaires sous forme de mousse
EP0275104A3 (en) Process for preparing 2,3-dihydro-1h-imidazolylalkoxyindene derivatives and pharmaceutically acceptable salts